Erasca (ERAS) Other financing activities (2020 - 2026)
Erasca's (ERAS) quarterly Other financing activities came in at $2.0 million in Q1 2026, up 5833.33% YoY from $33000.0 in Q1 2025, and up 667.84% on a QoQ basis from $255000.0 in Q4 2025.
Erasca (ERAS) Other financing activities (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Other financing activities data on file, last reported at $2.0 million in Q1 2026.
- Quarterly Other financing activities rose 5833.33% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (up 171.83% YoY) and the FY2025 annual result came in at $372000.0, down 55.5% from the prior year.
- Other financing activities grew to $2.0 million in Q1 2026, from $255000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $43.6 million in Q2 2024 to a low of -$43.2 million in Q3 2024.
- A 5-year average of $333823.5 and a median of $193000.0 in 2023 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 35648.36% in 2024, down 617200.0% in 2024.
- Tracing ERAS's Other financing activities over 5 years: stood at $742000.0 in 2022, then plunged by 73.99% to $193000.0 in 2023, then jumped by 105.18% to $396000.0 in 2024, then tumbled by 35.61% to $255000.0 in 2025, then surged by 667.84% to $2.0 million in 2026.
- The last three Other financing activities figures came in at $2.0 million (Q1 2026), $255000.0 (Q4 2025), and $41000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.60 Mn |
| Jun 30, 2026 | 2.60 Mn |
| Mar 31, 2026 | 1.96 Mn |
| Mar 31, 2026 | 1.96 Mn |
| Dec 31, 2025 | 255,000.00 |
| Dec 31, 2025 | 255,000.00 |
| Sep 30, 2025 | 41,000.00 |
| Sep 30, 2025 | 41,000.00 |
| Jun 30, 2025 | 43,000.00 |
| Jun 30, 2025 | 43,000.00 |
| Mar 31, 2025 | 33,000.00 |
| Mar 31, 2025 | 33,000.00 |
| Dec 31, 2024 | 396,000.00 |
| Dec 31, 2024 | 396,000.00 |
| Sep 30, 2024 | -43.20 Mn |
| Sep 30, 2024 | -43.20 Mn |
| Jun 30, 2024 | 43.61 Mn |
| Jun 30, 2024 | 43.61 Mn |
| Mar 31, 2024 | 24,000.00 |
| Mar 31, 2024 | 24,000.00 |